GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eutilex Co Ltd (XKRX:263050) » Definitions » Cash Ratio

Eutilex Co (XKRX:263050) Cash Ratio : 2.48 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Eutilex Co Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Eutilex Co's Cash Ratio for the quarter that ended in Mar. 2024 was 2.48.

Eutilex Co has a Cash Ratio of 2.48. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Eutilex Co's Cash Ratio or its related term are showing as below:

XKRX:263050' s Cash Ratio Range Over the Past 10 Years
Min: 1.43   Med: 5.05   Max: 31.43
Current: 2.48

During the past 9 years, Eutilex Co's highest Cash Ratio was 31.43. The lowest was 1.43. And the median was 5.05.

XKRX:263050's Cash Ratio is ranked worse than
54.58% of 1508 companies
in the Biotechnology industry
Industry Median: 2.97 vs XKRX:263050: 2.48

Eutilex Co Cash Ratio Historical Data

The historical data trend for Eutilex Co's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eutilex Co Cash Ratio Chart

Eutilex Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only 15.10 1.64 1.92 5.71 4.85

Eutilex Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.08 5.56 5.34 4.85 2.48

Competitive Comparison of Eutilex Co's Cash Ratio

For the Biotechnology subindustry, Eutilex Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eutilex Co's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eutilex Co's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Eutilex Co's Cash Ratio falls into.



Eutilex Co Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Eutilex Co's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=38238.663/7886.657
=4.85

Eutilex Co's Cash Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash Ratio (Q: Mar. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=27643.132/11148.006
=2.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eutilex Co  (XKRX:263050) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Eutilex Co Cash Ratio Related Terms

Thank you for viewing the detailed overview of Eutilex Co's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eutilex Co (XKRX:263050) Business Description

Traded in Other Exchanges
N/A
Address
Daeryung Technotown 17, Suite 1401, Gasan Digital 1-ro 25, Geumcheon-gu, Seoul, KOR, 08594
Eutilex Co Ltd is a Korean that operates in the anti-tumor immunotherapy market. The company develops anti-tumor T cell therapy and antibody therapeutics based on its immunotherapy technology. Its pipeline products include T Cell Therapy (4-1BB CTL), CAR-T, and Antibody.

Eutilex Co (XKRX:263050) Headlines

No Headlines